Global Diabetic Retinopathy Market
Dublin, Nov. 14, 2022 (GLOBE NEWSWIRE) -- The "Global Diabetic Retinopathy Market Size, Share & Industry Trends Analysis Report By Type, By Treatment Type, By Regional Outlook and Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.
The Global Diabetic Retinopathy Market size is expected to reach $7.7 billion by 2027, rising at a market growth of 11.3% CAGR during the forecast period.
Diabetic retinopathy is a critical medical disorder that affects the eyes as a result of diabetes or inefficient insulin level in the blood of the patient. Impairment to blood vessels of the light-sensitive tissue of the retina is the main cause of diabetic retinopathy. In addition, blurred vision, dark or empty spots in the vision, fluctuating vision, poor color identification, and vision loss are the most typical symptoms of this disorder.
A high sugar level in the blood causes blockage of the retina's small blood capillaries, impeding blood flow. Advanced cases of diabetic retinopathy require laser therapy or surgical operations. Mild-to-moderate instances of diabetic retinopathy can be cured with appropriate diabetes management.
Diabetic retinopathy may cause no symptoms or just minor vision abnormalities in the initial stages, however, it can result in blindness in advance stages. Anyone with type 1 or type 2 diabetes can develop the illness. The longer a person has diabetes, the more likely they are to develop ocular complications due to poorly regulated blood sugar levels. Diabetic retinopathy can progress to diabetic retinal detachment, macular edema, and neovascular glaucoma, among other serious eye disorders.
Diabetic retinopathy can also mutate to proliferative diabetic retinopathy, which is a more severe form of the disorder. Affected blood vessels close off in this type, leading the retina to develop new, dysfunctional blood vessels. These new blood vessels are fragile, and they may leak into the clear, jellylike fluid that fills the center of the eye of the patient.
Non-proliferative diabetic retinopathy, NPDR, is a kind of diabetic retinopathy in which symptoms are minimal or absent. New blood vessels are weakened or stop forming in this more prevalent form of diabetic retinopathy. The membranes of the blood vessels in the retina deteriorate when a patient suffers NPDR. Small bulges emerge from the smaller vessels' walls, occasionally blood and seeping fluid into the retina. Larger retinal vessels may also begin to dilate and their size becomes irregular.
COVID-19 Impact Analysis
The COVID-19 pandemic caused a severe impact to various economies all over the world. Several businesses were significantly devastated as a result of the outbreak of the COVID-19 infection. In addition, the governments of several countries were forced to impose lockdowns in their nations.
As a result, the manufacturing units of numerous goods were temporarily shut. Moreover, these lockdowns also caused a major disruption in the supply chain of various goods. Further, the COVID-19 led the worldwide healthcare industry to a significant failure due to the shortage of beds and oxygen in hospitals. The outbreak of COVID-19 all over the world has placed healthcare workflows in a disarray. Various industries, including numerous sub-domains of healthcare, have been forced to temporarily close their units because of the rising cases of infection.
Market driving Factors:
Rising number of diabetic patients
Diabetes is considered as the major origin of diabetic retinopathy. Therefore, an increase in the number of patients that are suffering from diabetes is expected to directly increase the demand for diabetic retinopathy treatments. In addition, there is a significant rise in the number of patients with diabetes, due to which, the requirement of diabetic retinopathy treatment is continuously increasing.
There is a significant number of people that are concerned about the damage that can be caused to their eyes by the occurrence of the diabetic retinopathy. The diabetic retinopathy market is expected to grow due to an increase in diabetes prevalence around the world. According to the National Center for Biotechnology Information, Diabetic retinopathy affected 126 million people in 2010, and it is expected to affect more than 191 million people by 2030.
Increasing geriatric population all over the world
Instances of the diabetic retinopathy are more common in geriatric people. The prevalence of this disorder is found to be more robust in people that are aging above 60.
Moreover, the number of elderly people is becoming significant and accounts for a substantial share of the population in nearly every country, affecting several aspects of society, including financial markets and labor, demand for goods and services, like housing, transportation, as well as social protection, along with family structures and intergenerational ties.
According to the United Nations Organization, the population of elderly people all over the world is expected to become more than double throughout the next three decades, reaching 1.5 billion by 2050.
Marketing Restraining Factor:
Lack of healthcare facilities in developing and under-developed economies
People residing in poor countries have lesser access to healthcare facilities than wealthy people, while the poor people have lesser access to healthcare services inside their own countries. In contrast, poor people in low- and Middle-income countries, or LMICs, are continuously disadvantaged in several aspects of access as well as their determinants.
Moreover, the healthcare sector in the least developed countries is poorly underfunded, and a vast majority of these countries are unable to provide basic and fundamental healthcare services to their citizens. This problem is most prevalent in under-developed and developing countries, where government's investments on public security is increasing at the cost of healthcare expenditure.
Key Topics Covered:
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
18.104.22.168 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Diabetic Retinopathy Market
Chapter 4. Global Diabetic Retinopathy Market by Type
4.1 Global Proliferative Market by Region
4.2 Global Diabetic Macular Edema (DME) Market by Region
Chapter 5. Global Diabetic Retinopathy Market by Treatment Type
5.1 Global Anti VEGF Drug Market by Region
5.2 Global Steroid Implants Market by Region
5.3 Global Laser Surgeries Market by Region
5.4 Global Vitrectomy Market by Region
Chapter 6. Global Diabetic Retinopathy Market by Region
Chapter 7. Company Profiles
7.1 Alimera Sciences, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
22.214.171.124 Partnerships, Collaborations, and Agreements:
126.96.36.199 Geographical Expansions:
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
188.8.131.52 Partnerships, Collaborations, and Agreements:
184.108.40.206 Approvals and Trials:
7.3 Bausch Health Companies, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
220.127.116.11 Partnerships, Collaborations, and Agreements:
18.104.22.168 Approvals and Trials:
7.4 Bayer AG
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
22.214.171.124 Approvals and Trials:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.6 Novartis AG
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Allergan PLC (AbbVie, Inc.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
126.96.36.199 Partnerships, Collaborations, and Agreements:
7.8 Regeneron Pharmaceuticals, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expense
188.8.131.52 Approvals and Trials:
7.9 Ampio Pharmaceuticals, Inc.
7.9.1 Company Overview
7.10. Kowa Company, Ltd.
7.10.1 Company Overview
For more information about this report visit https://www.researchandmarkets.com/r/i1yhrh
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900